Full Breakdown
Daily Multivitamin Shows Modest Gains in Functional Health for Older Adults
7/30/2026, 9:46:20 AM
Core Findings from the COSMOS Functional-Health Analysis
A secondary analysis of the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) evaluated functional health using the Kansas City Cardiomyopathy Questionnaire (KCCQ). Among 16,027 participants aged 60 or older, daily multivitamin use produced a statistically significant improvement of 0.45 points in symptom-burden scores and 0.30 points in the combined clinical-summary score compared with placebo. The effect was strongest in the 122 participants with carotid stenosis, who experienced average improvements of 6.75 points (symptom burden) and 6.01 points (clinical summary). Cocoa-extract supplementation did not affect overall functional scores, though a benefit was observed in the subgroup with congestive heart failure. The results were presented on July 27 at NUTRITION 2026, the annual meeting of the American Society for Nutrition.
Background & Context
COSMOS was a randomized, double-blind, placebo-controlled trial that originally enrolled 21,442 U.S. adults without major cardiovascular disease (men >= 60 y, women >= 65 y). Its primary aim was to assess cancer and major cardiovascular outcomes; the present analysis repurposes the same cohort to examine day-to-day functional health over three years.
Data & Statistics
- Total participants analyzed for functional health: 16,027.
- Average symptom-burden improvement: +0.45 points (multivitamin vs. placebo).
- Average clinical-summary improvement: +0.30 points.
- Carotid-stenosis subgroup (n = 122): +6.75 points symptom burden, +6.01 points clinical summary.
- Cocoa extract: no overall effect; significant benefit only in participants with congestive heart failure (exact magnitude not disclosed).
Official Statements & Responses
Lead author Bayu B. Co-author Yanbin Dong, MD, PhD, described the multivitamin benefit as “modest” and cautioned that it should not replace a nutritious diet or regular exercise. The investigators noted that sponsors (Mars, Pfizer, Haleon) had no role in study design, analysis, or interpretation.
Conflicting Reports & Gaps
Earlier publications from the same trial reported no cardiovascular-disease or cancer prevention benefit, creating a contrast with the current functional-health findings. The analysis relies on self-reported questionnaire data rather than objective performance measures, and the abstract has not undergone full peer review, limiting definitive conclusions.
Verbatim Quotes
- “What makes this work unique is our focus on functional health, how people actually feel and function in their daily lives—rather than just the prevention of major diseases,” — Bayu B. Bekele, said lead author
- “These benefits may be particularly relevant for individuals experiencing fatigue, shortness of breath or swelling in the feet, which can limit daily functioning,” — Bekele. Inside
- “This study is meaningful in that it focused on maintaining actual daily living abilities rather than disease prevention,” — Dr. Bekele, said lead author
- “Importantly, the multivitamin group was not suddenly able to do activities that the placebo group could not do,” — Bayu B. Bekele, said lead author
What’s Next
The authors describe the findings as hypothesis-generating and call for targeted clinical trials to confirm the larger benefit observed in participants with carotid stenosis or other vascular conditions. Future research will need to assess objective functional outcomes and explore mechanisms beyond self-reported symptom scores.
